Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Influence of Adiponutrin in Chronic Liver Disease

This study has been completed.
Sponsor:
Information provided by:
Erasme University Hospital
ClinicalTrials.gov Identifier:
NCT01122797
First received: May 11, 2010
Last updated: NA
Last verified: December 2002
History: No changes posted

May 11, 2010
May 11, 2010
January 2003
January 2010   (final data collection date for primary outcome measure)
Assessment of fibrosis and steatosis by liver biopsy in alcoholic liver disease patients.
After liver histology assessment for liver liver dammage a potential correlation of fibrosis and steatosis was studied with rs738409 PNPLA3 polymorphism
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Influence of Adiponutrin in Chronic Liver Disease
Study of Metabolism Influence in Human Alcoholic Liver Disease

Increasing evidence attests the influence of multiple metabolic genetic risk factors in the progression of alcoholic liver disease. Deleterious pathways involved in metabolism such as lipid peroxidation and cytokines have been implicated in promoting inflammation leading to fibrosis increase and liver injury progression. The aim of this study was to assess the role of rs738409 single nucleotide polymorphism in the PNPLA3 gene in alcoholic liver disease patients.

Not Provided
Observational
Observational Model: Case Control
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples With DNA
Description:

DNA extraction from whole blood sample. Piece of liver tissue in the alcoholic liver disease group.

Probability Sample

Consecutive patients undergoing transjugular liver biopsy for alcoholic liver disease will be included in the study to determine the potential correlation between rs738409 PNPLA3 polymorphism and/or PNPLA3 mRNA expression.

Alcoholic Liver Disease
Not Provided
  • Alcoholic liver disease
    Alcoholic liver disease patients undergoing a transjugular liver biopsy in our institution
  • Controls
    Healthy controls patients recruited from the Occupational Medicine Department during a routine physical examination.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
658
March 2010
January 2010   (final data collection date for primary outcome measure)

ALD patients:

Inclusion Criteria:

  • Excess alcohol intake
  • Abnormal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) or a suspicion of cirrhosis related to ALD
  • Caucasian ethnicity

Exclusion Criteria:

  • Presence of any other chronic liver disease
  • Co-infection with human immunodeficiency virus

Controls:

Inclusion Criteria:

  • Caucasian ethnicity

Exclusion Criteria:

  • Presence of a disease
Both
18 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
Belgium
 
NCT01122797
ET-PNPLA3
Yes
Eric Trépo, MD, Erasme University Hospital (Olivier Le Moine, MD, PhD)
Erasme University Hospital
Not Provided
Not Provided
Erasme University Hospital
December 2002

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP